交界可切除胰腺癌:概念演变与当前基于影像的分类方法
本综述从影像学角度梳理交界可切除胰腺癌的概念演变,讨论可切除、交界可切除与局部晚期或转移性疾病之间关键影像标准的争议,并总结支持新辅助治疗的证据及治疗前后的影像实践现状。
要点
- 交界可切除胰腺癌是介于可切除与局部晚期之间的独立亚群,R1切除相对更可能。
- 越来越多证据提示该群体可能从新辅助治疗中获益,以提高最终R0切除的可能性。
- 交界可切除的解剖与影像标准尚未 universally 达成一致,各分类系统与机构实践差异较大。
核心结论
- 临床医生与放射科医生应知悉交界可切除性影像标准的演变,因其对治疗策略、随访建议和预后有深远影响。
研究设计与样本
- 本综述从影像学视角追溯交界可切除性的概念演变,并讨论定义可切除、交界可切除与局部晚期或转移性疾病阈值的关键影像标准争议。
- 本综述还涉及支持该人群新辅助治疗的数据,并讨论治疗前与治疗期间的当前影像实践。
主要发现
- 越来越多证据提示交界可切除患者群体可能特别受益于新辅助治疗,以提高最终切缘阴性(R0)切除的可能性。
- 定义交界可切除性的解剖与影像标准尚未 universally 达成一致,文献中提出了多种分类系统,且机构间实践存在相当大差异。
- 由于缺乏共识、患者总数少以及缺乏专门针对交界可切除患者的确立临床试验,该亚群准确的循证诊断分类与治疗选择仍是一项重大挑战。
局限性
- 解剖与影像标准尚未 universally 达成一致,文献中提出多种分类系统,机构间实践差异相当大。
- 缺乏共识、患者总数少以及缺乏专门针对交界可切除患者的确立临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnostic imaging plays a critical role in the initial diagnosis and therapeutic monitoring of pancreatic adenocarcinoma. Over the past decade, the concept of 'borderline resectable' pancreatic cancer has emerged to describe a distinct subset of patients existing along the spectrum from resectable to locally advanced disease for whom a microscopically margin-positive (R1) resection is considered relatively more likely, primarily due to the relationship of the primary tumor with surrounding vasculature. MATERIALS AND METHODS: This review traces the conceptual evolution of borderline resectability from a radiological perspective, including the debates over the key imaging criteria that define the thresholds between resectable, borderline resectable, and locally advanced or metastatic disease. This review also addresses the data supporting neoadjuvant therapy in this population and discusses current imaging practices before and during treatment. RESULTS: A growing body of evidence suggests that the borderline resectable group of patients may particularly benefit from neoadjuvant therapy to increase the likelihood of an ultimately margin-negative (R0) resection. Unfortunately, anatomic and imaging criteria to define borderline resectability are not yet universally agreed upon, with several classification systems proposed in the literature and considerable variance in institution-by-institution practice. As a result of this lack of consensus, as well as overall small patient numbers and lack of established clinical trials dedicated to borderline resectable patients, accurate evidence-based diagnostic categorization and treatment selection for this subset of patients remains a significant challenge. CONCLUSIONS: Clinicians and radiologists alike should be cognizant of evolving imaging criteria for borderline resectability given their profound implications for treatment strategy, follow-up recommendations, and prognosis.
引用
- Gilbert JW, Wolpin B, Clancy T, et al. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017. PMID: 28407088. doi:10.1093/annonc/mdx180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。